178 Results for "

Irak4

" in MedChemExpress (MCE) Product Catalog:
Products (178)

178 Results for "Irak4" in MCE Product Catalog:

76
76 Publications Verification
Art. -Nr.: HY-50937
CAS. Nr.: 894787-30-5
Target:  

MyD88

Forschungsgebiete:  

Inflammation/Immunology

ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity .
loading...
    loading...
33
33 Cited Publications
Art. -Nr.: HY-103490
CAS. Nr.: 1111556-37-6
Reinheit:  99.41%
Synonyms: EDHS-206
Target:  

MAP3K Apoptosis

Forschungsgebiete:  

Infection Inflammation/Immunology Cancer

Takinib (EDHS-206) is an orally active and selective TAK1 inhibitor (IC50=9.5 nM), more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. Takinib is an inhibitor of autophosphorylated TAK1 that non-competitively binds within the ATP binding pocket. Takinib induces apoptosis following TNFα stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. Takinib is also a P. falciparum protein kinase 9 (PfPK9) inhibitor (KD(app) of 0.46 μM) .
loading...
    loading...
14
14 Cited Publications
Art. -Nr.: HY-B1829
CAS. Nr.: 312-93-6
Synonyms: Dexamethasone 21-phosphate
Dexamethasone phosphate (Dexamethasone 21-phosphate) is a prodrug form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone phosphate is prepared by introducing a phosphate ester group to the hydroxyl group at position 21 of the Dexamethasone molecule. Dexamethasone phosphate inhibits LPS (HY-D1056)-induced degradation of IRAK-1 and IRAK-4, and blocks LPS-induced activation of TRAF6, p-TAK1 and p-JNK. Dexamethasone phosphate inhibits the secretion of RANTES, TGF-β1 and NO, promotes the production of MIP-1α and IL-10, and blocks microglial migration. Dexamethasone phosphate is almost completely converted to Dexamethasone in rat blood, and supports transdermal delivery via iontophoresis. Dexamethasone phosphate can be used in research related to steroid-dependent ulcerative colitis, chemotherapy-induced vomiting, allergic asthma and acute colitis (inflammatory bowel disease) [4] .
loading...
    loading...
14
14 Cited Publications
Art. -Nr.: HY-B1829A
CAS. Nr.: 2392-39-4
Synonyms: Dexamethasone 21-phosphate disodium
Dexamethasone phosphate (Dexamethasone 21-phosphate) disodium is a prodrug form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone phosphate disodium is produced by introducing a phosphate ester group at the 21-position of the Dexamethasone molecule, forming a salt with sodium ions, thereby significantly improving water solubility. Dexamethasone phosphate disodium inhibits LPS (HY-D1056)-induced degradation of IRAK-1 and IRAK-4, and blocks LPS-induced activation of TRAF6, p-TAK1 and p-JNK. Dexamethasone phosphate disodium inhibits the secretion of RANTES, TGF-β1 and NO, promotes the production of MIP-1α and IL-10, and blocks microglial migration. Dexamethasone phosphate disodium is almost completely converted to Dexamethasone in rat blood, and supports transdermal delivery via iontophoresis. Dexamethasone phosphate disodium can be used in research related to steroid-dependent ulcerative colitis, chemotherapy-induced vomiting, allergic asthma and acute colitis (inflammatory bowel disease) [4] .
loading...
    loading...
10
10 Cited Publications
Art. -Nr.: HY-14721
CAS. Nr.: 1100598-32-0
Reinheit:  99.94%
Synonyms: EMD-1214063
Target:  

c-Met/HGFR Autophagy

Forschungsgebiete:  

Cancer

Tepotinib (EMD-1214063) is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC50 of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib inhibits c-Met phosphorylation and induces autophagy. Tepotinib has antitumor effects .
loading...
    loading...
9
9 Cited Publications
Art. -Nr.: HY-19836
CAS. Nr.: 1817626-54-2
Synonyms: PF-06650833
Target:  

IRAK

Forschungsgebiete:  

Inflammation/Immunology

Zimlovisertib (PF-06650833) is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC50s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. Zimlovisertib is used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas .
loading...
    loading...
8
8 Cited Publications
Art. -Nr.: HY-135317
CAS. Nr.: 1801344-14-8
Reinheit:  99.96%
Synonyms: CA-4948
Forschungsgebiete:  

Inflammation/Immunology Cancer

Emavusertib is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib exhibits antitumor activity in mouse model
loading...
    loading...
6
6 Cited Publications
Art. -Nr.: HY-103017A
CAS. Nr.: 2227368-54-7
Reinheit:  99.03%
Target:  

IRAK

Forschungsgebiete:  

Infection Inflammation/Immunology Cancer

JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 ameliorates LPS-induced sepsis in mice . JH-X-119-01 inhibits IRAK1 biochemically with an apparent IC50 of 9 nM while exhibiting no inhibition of IRAK4 at concentrations up to 10 μM .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-145483
CAS. Nr.: 2432994-31-3
Reinheit:  99.77%
Synonyms: KYM-001; PROTAC Irak4 degrader-7
Target:  

PROTACs IRAK Apoptosis

Forschungsgebiete:  

Inflammation/Immunology Cancer

KT-474 (KYM-001; PROTAC IRAK4 degrader-7) is an orally active PROTAC IRAK4 degrader with anti-tumor effects. KT-474 inhibits the cell cycle and induces apoptosis. KT-474 induces tumor regression in a xenograft model of MYD88-mutated ABC DLBCL .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-145483A
CAS. Nr.: 2751703-31-6
Synonyms: KYM-001 hydrochloride; PROTAC Irak4 degrader-7 hydrochloride
Target:  

PROTACs IRAK Apoptosis

Forschungsgebiete:  

Inflammation/Immunology

KT-474 (KYM-001; PROTAC IRAK4 degrader-7) hydrochloride is an orally active PROTAC IRAK4 degrader with anti-tumor effects. KT-474 inhibits the cell cycle and induces apoptosis. KT-474 induces tumor regression in a xenograft model of MYD88-mutated ABC DLBCL .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-146244
CAS. Nr.: 525625-52-9
Reinheit:  98.32%
Synonyms: ODN 2006; PF-3512676; CpG 7909; ODN 7909
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC50 of 180 nM against human TLR9. Agatolimod activates and upregulates the expression of both TLR9 and TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis [4] .
loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-139374
CAS. Nr.: 1931994-81-8
Reinheit:  98.14%
Synonyms: BAY 1834845
Target:  

IRAK

Forschungsgebiete:  

Inflammation/Immunology

Zabedosertib (BAY 1834845) is a selective, orally active IRAK4 inhibitor with immunomodulatory potential, IC50 is 3.55 nM. IRAK4 is a protein kinase involved in signaling innate immune responses from Toll-like receptors . Zabedosertib exhibits anti-inflammatory property against IL-β, LPS (HY-D1056) and Imiquimod (HY-B1080) induced inflammation .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-129966
CAS. Nr.: 2360533-90-8
Reinheit:  99.77%
Target:  

PROTACs IRAK

Forschungsgebiete:  

Cancer

PROTAC IRAK4 degrader-1 (compound I-210) is a Cereblon-based IRAK4 PROTAC degrader .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-111101
CAS. Nr.: 2196204-23-4
Reinheit:  98.07%
Target:  

IRAK

Forschungsgebiete:  

Cancer

AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC50 values of 0.005 μM and 0.023 μM, respectively. AZ1495 has IRAK4 inhibition with a Kd value of 0.0007 μM. AZ1495 can be used for the research of diffuse large B-cell lymphoma (DLBCL) .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-114181
CAS. Nr.: 1850276-58-2
Reinheit:  99.55%
Forschungsgebiete:  

Inflammation/Immunology

IRAK4-IN-4 (Compound 15) is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, with an IC50 of 2.8 nM. IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase (cGAS) with an IC50 of 2.1 nM. IRAK4-IN-4 can be used for research of autoimmune diseases .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-13278
CAS. Nr.: 1012104-68-5
Reinheit:  99.77%
Target:  

IRAK

Forschungsgebiete:  

Inflammation/Immunology

IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4(IRAK4) inhibitor.
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-153368
CAS. Nr.: 2655656-99-6
Reinheit:  95.43%
Synonyms: KT-413
Forschungsgebiete:  

Cancer

Zomiradomide (KT-413) is an orally active IRAK4 PROTAC degrader with a DC50 of 6 nM. Zomiradomide inhibits the NF-κB signaling pathway, while its molecular glue function mediates the degradation of Ikaros and Aiolos (with a DC50 of 1 nM for both), activates the IFN-I signaling pathway, and selectively degrades IMiD substrates. Zomiradomide inhibits cancer cell proliferation and tumor growth. Zomiradomide can be used in research related to B-cell non-Hodgkin's lymphoma and diffuse large B-cell lymphoma .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-150741
CAS. Nr.: 332437-00-0
Reinheit:  97.92%
ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-150741C
Reinheit:  97.92%
Forschungsgebiete:  

Cancer

ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 sodium interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus .
loading...
    loading...
Art. -Nr.: HY-18992
CAS. Nr.: 1287665-60-4
Target:  

IRAK

Forschungsgebiete:  

Inflammation/Immunology

AS2444697 is an orally active IRAK-4 inhibitor with an IC50 of 21 nM . AS2444697 potently inhibits human and rat IRAK-4 activity. AS2444697 exhibits renoprotective effects through anti-inflammatory action .
loading...
    loading...